ARTINIUS Trademark

Trademark Overview


On Friday, October 18, 2019, a trademark application was filed for ARTINIUS with the United States Patent and Trademark Office. The USPTO has given the ARTINIUS trademark a serial number of 88660316. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 27, 2023. This trademark is owned by Bristol-Myers Squibb Company. The ARTINIUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; P...
artinius

General Information


Serial Number88660316
Word MarkARTINIUS
Filing DateFriday, October 18, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 27, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 1, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 22, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Monday, November 27, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 27, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, April 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 14, 2023SOU EXTENSION 5 GRANTED
Thursday, April 6, 2023SOU EXTENSION 5 FILED
Thursday, April 13, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, April 6, 2023SOU TEAS EXTENSION RECEIVED
Saturday, October 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 6, 2022SOU EXTENSION 4 GRANTED
Thursday, October 6, 2022SOU EXTENSION 4 FILED
Thursday, October 6, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, April 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 8, 2022SOU EXTENSION 3 GRANTED
Friday, April 8, 2022SOU EXTENSION 3 FILED
Friday, April 8, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 27, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 25, 2021SOU EXTENSION 2 GRANTED
Monday, October 25, 2021SOU EXTENSION 2 FILED
Monday, October 25, 2021SOU TEAS EXTENSION RECEIVED
Thursday, April 1, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 30, 2021SOU EXTENSION 1 GRANTED
Tuesday, March 30, 2021SOU EXTENSION 1 FILED
Tuesday, March 30, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, October 27, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 1, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 1, 2020PUBLISHED FOR OPPOSITION
Wednesday, August 12, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, July 29, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 27, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, July 26, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, July 26, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 28, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 28, 2020NON-FINAL ACTION E-MAILED
Tuesday, January 28, 2020NON-FINAL ACTION WRITTEN
Friday, January 24, 2020ASSIGNED TO EXAMINER
Tuesday, October 22, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED